Hologic Inc

Hologic — Debt Investor Presentation (July 2013)

30 slides from Hologic's debt investor presentation, Jul 23, 2013

  1. Slide 1: Presentation to Lenders

    Exhibit 99.1 Presentation to Lenders July 23, 2013

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking information that involves risks and uncertainties, including statements about the Company’s plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information included herei

  3. Slide 3: Third Quarter Fiscal 2013 Preliminary Financial Information

    Third Quarter Fiscal 2013 Preliminary Financial Information The preliminary financial information presented in this presentation represents estimates only, as the Company has not completed its financial statements for its third quarter ended June 29, 2013 and its independent auditor has not complete

  4. Slide 4: Transaction Overview

    Transaction Overview Hologic, Inc. ("Hologic" or "the Company") (NASDAQ: HOLX) is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women Hologic has continued to demonstr

  5. Slide 5: Pro Forma Capitalization

    Pro Forma Capitalization Amounts as of March 30, 2013 ($ in millions) Current Pro Forma Amount Amount Leverage Maturity Put Date Cash $ 745 $ 545 Revolver ($300mm) - - 0.0 x Aug-17 Term Loan A 969 969 1.0 x Aug-17 Extant Term Loan B 1,479 - 1.0 x Aug-19 New Term Loan B - 1,279 2.3 x Aug-19 Total Sec

  6. Slide 6: Total Revenues by Business Segment

    Total Revenues by Business Segment Consolidated Non-GAAP Q2’13 Revenues of $619.1M (unaudited)* Total Diagnostics $302.9M* 49% 19% Capital Equipment Breast Health $220.1M 35% 15% 66% Consumables Service GYN Surgical $73.7M 12% Skeletal Health $22.4M 4% Consumables/Service ~81% Capital Equipment ~19%

  7. Slide 7: Two Exciting New Product Cycles are Just Beginning

    Two Exciting New Product Cycles are Just Beginning • Early stage of a promising replacement cycle with technology superior to 2D digital • Recent peer-reviewed publications further support adoption Dimensions 3D Breast Tomosynthesis • Ability to offer class-leading automation to low- and medium-volu

  8. Slide 8: Diagnostics – Leadership in Cytology and Molecular Diagnostics

    Diagnostics – Leadership in Cytology and Molecular Diagnostics • Premier automated solutions • Proprietary chemistries: TMA (Transcription-mediated amplification) and Invader • Extending leadership from cytology into molecular via Gen-Probe acquisition • Validated by #1 or #2 U.S. market share in ke

  9. Slide 9: Comprehensive Cervical Cancer Screening Solution

    Comprehensive Cervical Cancer Screening Solution • The only FDA approved complete cervical cancer screening solution to include liquid-based cytology + HPV (high-risk and genotyping) • All from our ThinPrep vial, the gold standard in cervical cytology • Thoughtfully designed HPV products designed to

  10. Slide 10: Flagship Brand in STD Testing

    Flagship Brand in STD Testing • APTIMA Combo 2 assay remains a growth driver • < 40% of sexually active women aged 25 and under in the U.S. are screened for chlamydia and gonorrhea • Improved compliance and international expansion opportunities • APTIMA Trichomonas experiencing rapid adoption • Tric

  11. Slide 11: Broad Portfolio of MDx Instrumentation

    Broad Portfolio of MDx Instrumentation V o l u m e Reference Labs Hospital Labs Uniquely Positioned in Molecular Diagnostics • Already leading in high-volume setting • Ability to capitalize on lab decentralization trend with introduction of PANTHER • Proprietary chemistries, TMA and INVADER, offer f

  12. Slide 12: Integrated Sales Organization with a Clear Strategy

    Integrated Sales Organization with a Clear Strategy Combined Sales Call Point Molecular Lab Cytology Lab Physician Drive Test Utilization Drive Compliance Communicate Guidelines Portfolio of Products Combined Company Menu HPV CT/NG Trichomonas ThinPrep fFn - APTIMA & Imaging - Cervista - Genotyping

  13. Slide 13: Our Lab Partners

    Our Lab Partners The value of a Hologic partnership to our Lab Partners: • Grow revenue • Increase operational effectiveness • Provide patients and clinicians with leading women's health diagnostic solutions 13

  14. Slide 14: Breast Health – Mammography

    Breast Health – Mammography Leader in Breast Cancer Screening & Diagnosis • Market leadership: ~65% of current U.S. installed base, ~40% OUS • Approximate $4 billion addressable U.S. market • Strong competitive advantages of 3D Dimensions Clinical superiority to 2D First-to-market with no U.S. compe

  15. Slide 15: Advancing Breast Cancer Screening

    Advancing Breast Cancer Screening 15

  16. Slide 16: 3D Dimensions Tomosynthesis

    3D Dimensions Tomosynthesis Superior Next-Generation Digital Mammography Improved Tissue Visualization and Detection Superiority over 2D Digital Mammography Lower Recall Rates Tomosynthesis…uptake ahead of expectations • U.S. installed base of ~11,000 digital systems – potential for conversion to To

  17. Slide 17: Tomosynthesis Clinical Efficacy

    Tomosynthesis Clinical Efficacy Oslo Tomosynthesis Screening Trial Compared to 2D, U.S. sites report a reported breast cancer screening significant reduction in recalls with with Hologic Tomosynthesis significantly Hologic Tomosynthesis 2-3 1 improves cancer detection 40% 27% in invasive overall in

  18. Slide 18: Tomosynthesis + C-View 2D: A superior mammography exam

    Tomosynthesis + C-View 2D: A superior mammography exam 1 • Less patient dose through reduced x-ray exposures • Greater patient comfort via fast, 4 second scan time • Heightened detail from tomosynthesis images • Superior performance compared to traditional 2D alone 1. Compared to 2D alone. FDA PMA s

  19. Slide 19: MyoSure a Growth Driver in GYN Surgical

    MyoSure a Growth Driver in GYN Surgical MyoSure Hysteroscopic Tissue Removal System • Minimally-invasive technology to remove fibroids and polyps • Dynamic technology in early stages of adoption • Potential $300-400 million annual opportunity in the U.S. • Product line extensions offer flexibility t

  20. Slide 20: Q2 FY 2013 Overview

    Q2 FY 2013 Overview Quarter Ended March 30, 2013 (unaudited) Key Performance Metrics Q2 FY 2013 GAAP revenues of $612.7 million and non-GAAP Revenues* revenues of $619.1 million 1 • Non-GAAP revenues up $147.9 million, or 31.4%, vs. Q2’12 • Non-GAAP revenues down $25.5 million, or 4.0%, vs. Q1’13 GA

  21. Slide 21: Q2 FY 2013 Summary

    Q2 FY 2013 Summary Financing Activities • Sale of LIFECODES business unit for approximately $85 million in cash, adjusted for working capital items, with the opportunity to earn a contingent payment of $10 million • Successful transaction retiring $370 million, 2.00% Convertible Senior Notes due 203

  22. Slide 22: Business Segments

    Business Segments Breakdown of consolidated Non-GAAP Q2’13 Revenues of $619.1M (unaudited)* 49% 66% Diagnostics Consumables 12% GYN Surgical 15% 35% Service 19% Breast Health Capital Equipment U.S. Revenues ~ 75% Disposables/Service ~ 81% International Revenues ~ 25% Capital Equipment ~ 19% * Q2’13

  23. Slide 23: Q2 FY 2013 Diagnostics Summary

    Q2 FY 2013 Diagnostics Summary Diagnostics • Continued #1 U.S. market share for ThinPrep • Continued #1 U.S. market share for APTIMA Combo 2 for CT/GC • Continued #1 U.S. market share for PROCLEIX in blood screening • Continued competitive wins for ThinPrep, HPV and CT/GC • PANTHER launch progressin

  24. Slide 24: Q2 FY 2013 Breast Health Summary

    Q2 FY 2013 Breast Health Summary Breast Health • Continued #1 U.S. market share for digital mammography placements in the U.S. • Successfully met two-year unit tomosynthesis goal by end of Q2’13 and the goal is to more than double year-over-year placements in Fiscal 2013 • Record biopsy sales both i

  25. Slide 25: Q2 FY 2013 GYN Surgical Summary

    Q2 FY 2013 GYN Surgical Summary GYN Surgical • #1 share for MyoSure in the U.S. hysteroscopic morcellation market • Continued #1 market share for NovaSure in the GEA (Global Endometrial Ablation) market • Strong quarter for MyoSure with double-digit sequential and year-over-year growth • Growing dem

  26. Slide 26: Amendment Overview

    Amendment Overview Hologic is seeking to reprice its Term Loan B The amendment would also expand the Company’s general basket for Restricted Junior Payments to $250mm and increase the total net leverage threshold for accessing the excess cash flow builder component from 3.5x to 4.0x In addition, the

  27. Slide 27: Slide 27

  28. Slide 28: Reconciliation of GAAP to Non-GAAP

    Reconciliation of GAAP to Non-GAAP (unaudited) In thousands, except earnings per share Three Months Ended March 30, 2013 March 24, 2012 December 29, 2012 REVENUES GAAP revenues $612,663 - $631,362 Net adjustments primarily related to Novartis 6,429 - 13,275 collaboration Non-GAAP revenues $619,092 $

  29. Slide 29: Reconciliation of GAAP to Non-GAAP (unaudited)

    Reconciliation of GAAP to Non-GAAP (unaudited) In thousands, except earnings per share Three Months Ended March 30, 2013 March 24, 2012 December 29, 2012 OPERATING EXPENSES GAAP operating expenses $273,784 $215,976 $218,444 Adjustments: Amortization of intangible assets (28,667) (16,629) (28,526) Co

  30. Slide 30: Use of Non-GAAP Financial Measures

    Use of Non-GAAP Financial Measures Hologic has presented the following non-GAAP financial measures in this presentation: revenues; gross margins; operating expenses; operating income; interest expense; pre-tax income; net income; EPS; and EBITDA. Hologic defines its non-GAAP revenues to primarily in

Hologic — Debt Investor Presentation (July 2013) on 6ix